My ePortfolio Register   

Durable responses to avelumab in patients with Merkel cell carcinoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.04.17
Views: 885

Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, New Brunswick, USA

Dr Kaufman speaks with ecancer at AACR 2017 about the effectiveness of anti-PD-L1 avelumab in treating Merkel cell carcinoma (MCC) in patients who had been previously treated with chemotherapy.

He describes results from 88 patients with metastatic disease, who at 6 months follow-up had 31% response, and 33% response at 1 year.

Dr Kaufman notes the recent FDA approval of avelumab in this setting, and considers other possible applications.

You can read more about these results here.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence